Active	Status	Sponsor type	Region	Phase	Filter
4 Active 5 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Schostak, Martin
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients	Recruiting	3	250	Europe	Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel	Jena University Hospital, Bayer	Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)	07/25	01/27
OPTIMUM, NCT05220501: Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI	Completed	N/A	804	Europe, Canada, US	Micro-US Targeted Biopsy, MRI Targeted Biopsy	Sunnybrook Health Sciences Centre, Exact Imaging	Prostate Cancer	09/24	11/24